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Abstract
Background:  Imatinib is a tyrosine-kinase inhibitor; for which there is limited information
regarding its effects on AIDS Kaposi's sarcoma and none in patients with transplant-associated
Kaposi's sarcoma. Sirolimus, an immunosuppressive drug used for kidney transplant, exhibits
antiangiogenic activity related to impaired production of VEGF (vascular endothelial growth factor),
clinical benefit has been reported in Kaposi's sarcoma associated with renal graft.
Case Presentation: Here we report a case of an 80 year old male, who developed Kaposi's
Sarcoma nine months after receiving a living non-related donor kidney transplant at age 74. Three
years after treatment with different chemotherapeutic agents for progressive cutaneous Kaposi's
Sarcoma with no visceral involvement, he was prescribed Imatinib (200 mg/day for two weeks
followed by 400 mg/day) after four weeks of treatment he developed anasarca, further progression
of KS and agranulocytosis. Imatinib was discontinued and there was significant clinical recovery.
One year later his immunosuppressive therapy was changed to Sirolimus and regression of the
Kaposi's sarcoma occurred.
Conclusion: The lack of benefit and severe toxicity associated with the use of Imatinib in this
patient should alert clinicians of potentially adverse consequence of its use in patients with
transplant associated Kaposi's sarcoma. On the other hand the positive response seen in this
patient to Sirolimus even after a long evolution of Kaposi's sarcoma, multiple chemotherapy
regimens and extensive cutaneous disease further suggest it therapeutical utility for transplant
associated Kaposi's sarcoma.
Background
Since the identification of Human Herpes 8 (HHV-8) in
1994, [1,2] there have been great advances in the under-
standing of the pathogenesis of Kaposi's sarcoma (KS).
The better understanding of autocrine and paracrine fac-
tors in the proliferation and differentiation of KS cells [3]
has provided a potential benefit derived from targeted
therapy, a therapeutic field which has achieved an enor-
mous development over the last decade. There are few
reports regarding novel treatment options for KS, this
includes the use of Imatinib in AIDS KS [4] and the use of
Sirolimus in renal transplant KS patients [5].
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Imatinib is a tyrosine-kinase inhibitor that induces apop-
tosis in Bcr-Abl positive cell lines, platelet-derived growth
factor positive cells and c-kit positive gastrointestinal stro-
mal cells. Limited information exists regarding its effects
on KS cells [4]. Though the drug safety profile is good it
can induce severe adverse events [6]. Because Imatinib is
metabolized through the CYP3A3 enzyme it can result in
adverse drugs interaction. Its safety in patients with renal-
insufficiency or kidney graft is unknown.
HHV-8 up-regulates the vascular endothelial growth fac-
tor (VEGF) receptor Flk-1/KDR in endothelial cells. In
vitro infection of human primary endothelial cells with
HHV-8 causes long-term proliferation and survival of
cells. Blocking the interaction between VEGF and Flk-1/
KDR can abolish VEGF induced proliferation. Sirolimus
an immunosuppressive drug used in kidney transplanta-
tion [5], exhibits antiangiogenic activity related to
impaired production of VEGF and limited proliferative
response of endothelial cells to stimulation by VEGF,
therefore inhibiting KS progression.
Here we report a case of a kidney transplant patient who
after unsuccessful treatments with different chemothera-
peutics was given Imatinib for refractory and extensive
cutaneous KS that resulted in severe toxicity and no clini-
cal benefit. In contrast shifting the patient's immunosup-
pressive maintenance therapy to Sirolimus led within one
year to over 80% regression of the KS and is still showing
sign of regression (Table 1)
Case Presentation
The patient is an 80 year old male with diabetes mellitus
and hypertension, who at age 74 (March 2001) had
received a living non-related donor kidney transplant. At
that time he was discharged with a double immunosup-
pressive therapy consisting of prednisone 20 mg/day and
mophetil mycophenolate 1.5 gr/day. No calcineurin
inhibitor was administered. His prednisone dose was fur-
ther decreased to 5 mg/day and mophetil mycophenolate
doses sustained. In November 2001 he developed cutane-
ous purple elevated lesions in his lower limbs that were
diagnosed as KS by skin biopsy. He received 19 adminis-
trations of vincristine (1 mg) and bleomycin (15 mg)
weekly that resulted in flattening and fading of the
lesions. Treatment was discontinued for two months, and
KS recurred, with pain and edema in both legs.
On July 2002, with an almost 100% involvement of his
lower limbs skin with KS but no visceral involvement he
received 50 mg of liposomal-adriamycin. In addition, he
was then prescribed valganciclovir 450 mg BID (corrected
for creatinine clearance) [7] and three additional admin-
istrations of liposomal-adriamycin, up to December
2002. He showed 40% response again with early relapse.
On January 2003 the patient developed disseminated her-
pes zoster, which was treated with IV acyclovir.
In May 2003 KS progression was observed and received
radiotherapy with no benefit Figure 1. In August 2003 he
started oral etoposide at 50 mg QD for two weeks fol-
lowed by two weeks off until May 2004 achieving a very
slow 50% response. Tolerance was good and serum creat-
inine remain stable at around 1,4 mg/dl. Mophetil myco-
phenolate dose was reduced to 1 g/day and prednisone to
2.5 mg/day.
On May 2004 the patient requested a second opinion and
was prescribed Imatinib 200 mg qd for two weeks fol-
lowed by 400 mg qd. After four weeks of Imatinib, his
health deteriorated rapidly, he developed anasarca, wors-
ening of KS, his serum creatinine increased from 1.4 mg/
dl to 2.3 mg/dl and he developed grade 4 granulocytope-
nia (Figure 2). The patient was hospitalized with fever and
was started on IV antibiotics and daily G-CSF for four days
after which his WBC count normalized. Two weeks later
the creatinine level returned to 1.5 mg/dl. On February
2005 he was started on 30 mg of paclitaxel IV every three
weeks. After three courses with no clinical benefit he
developed a skin rash that prompted discontinuation.
On April 2005, he was started on Sirolimus 2 mg a day,
and after 8 weeks escalated to 4 mg a day. Three weeks
later mophetil mycophenolate and prednisone were dis-
Table 1: 
Date Event
August 2000 End stage renal disease started on hemodyalisis (79 years old male).
March 2001 Living non-related donor kidney transplant.
November 2001 Diagnosed with Kaposi's Sarcoma.
Three year chemotherapy (vincristine-belomycin) (liposomal adriamycin)
June 2004 Imatinib
July 2004 Agranulocitosis, anasarca increase in creatinine.
February 2005 Placitaxel (developed allergic rash).
April 2005 Change immunosuppressive therapy for Sirolimus.
November 2006 Persistent Kaposi's Sarcoma regression, still on Sirolimus.BMC Nephrology 2007, 8:6 http://www.biomedcentral.com/1471-2369/8/6
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continued. Sustained and significant KS regression was
evident after 16 weeks, but he developed a basal cell carci-
noma and pneumonia that required hospital admission;
Sirolimus dose was lowered to 2 mg a day. Thereafter his
clinical course has been satisfactory with continuous and
progressive regression of KS lesions (Figure 3). His serum
creatinine has remained under 1.6 mg/dl and he has not
developed new infectious episodes.
Conclusion
KS is a proliferative disease, cytokine mediated, where the
presence of the Human Herpes virus 8 is essential for the
process, and immunesuppression is a necessary fact [8].
The disease is insidious and with an unpredictable course;
when there is no visceral involvement, it is usually not life
threatening. [3]
It has been recognized that glucocorticoids have a major
role in KS development, [9-11] and their withdrawal may
induce regression of KS lesions [12,13]. In vitro they have
a synergistic effect with oncostatin, an autocrine element
involved in KS-cells proliferation.
A wide variety of therapies have been used for KS, includ-
ing interferon [14,15] and different chemotherapeutic
regimens [16]. Recently Imatinib has been used in KS
AIDS patients with short periods of observation [4]. In
addition, a recent study demonstrated that Siroliumus
inhibited progression of dermal KS in kidney transplanted
patients with an outstanding clinical outcome [5].
There is currently no evidence of imatinib effectiveness in
transplant associated-KS patients; and there is therefore
no basis for its prescription in this group of patients.
Moreover, in the case we are reporting, Imatinib not only
had no clinical benefit but resulted in life threatening tox-
icity. In contrast in this patient Sirolimus treatment was
associated with extensive regression of severe cutaneous
KS even after a long-standing and extended disease, and
multiple previous chemotherapy treatments (Table 1).
Sirolimus exhibits antiangiogenic activity related to
impaired production of VEGF and limiting proliferative
response of endothelial cells to stimulation by VEGF, lim-
iting the progression of KS. The KS regression in this case
Patient developed anasarca with rapid progression of  Kaposi's Sarcoma after four weeks of taking Imatinib (June  2004) Figure 2
Patient developed anasarca with rapid progression of 
Kaposi's Sarcoma after four weeks of taking Imatinib (June 
2004). Kaposi's sarcoma progressions after chemotherapy with- drawal, both lower limbs were completely covered with  Kaposi's Sarcoma (June 2003) Figure 1
Kaposi's sarcoma progressions after chemotherapy with-
drawal, both lower limbs were completely covered with 
Kaposi's Sarcoma (June 2003).BMC Nephrology 2007, 8:6 http://www.biomedcentral.com/1471-2369/8/6
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cannot be solely attributed to prednisone withdrawal,
since he had been on very low doses of prednisone (2.5
mg qd) months before Sirolimus was initiated. Our
results corroborate therapeutic benefit of Sirolimus in kid-
ney graft recipients[5,17,18] both as an immunosuppres-
sant to prevent graft rejection and to induce long standing
KS regression.
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Extensive regression of Kaposi Sarcoma after immune-sup-
pression was changed to Sirolimus, (14 months later), he 
only has hyperpigmented areas at knee levels, skin looks thin 
and delicate and easily bruised (July 2006).